Accepted Manuscript

Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma

Chia-Yen Lu, Gregory J. Chen, Pei-Han Tai, Yu-Chen Yang, Yu-Shen Hsu, Mingi Chang, Chuan-Lung Hsu

PII: S0006-291X(16)30435-1

DOI: 10.1016/j.bbrc.2016.03.124

Reference: YBBRC 35556

To appear in: Biochemical and Biophysical Research Communications

Received Date: 22 March 2016

Accepted Date: 25 March 2016

Please cite this article as: C.-Y. Lu, G.J. Chen, P.-H. Tai, Y.-C. Yang, Y.-S. Hsu, M. Chang, C.-L. Hsu, Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma, *Biochemical and Biophysical Research Communications* (2016), doi: 10.1016/j.bbrc.2016.03.124.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma

Chia-Yen Lu^a, Gregory J. Chen^a, Pei-Han Tai^a, Yu-Chen Yang^a, Yu-Shen Hsu^b, Mingi Chang^b,

Chuan-Lung Hsu^{a, *}

^a Institute of Biologics, Development Center for Biotechnology, New Taipei City, Taiwan

^b Laboratory of Biopharmaceutical Research, Advagene Biopharma, Taipei, Taiwan

*Corresponding author at:

Development Center for Biotechnology, Institute of Biologics; 101, Lane 169, Kangning St.

Xizhi District; New Taipei City 22180, Taiwan, R.O.C.

E-mail address: fabio@dcb.org.tw

Tel: +886.2.2695.6933 Ext. 5319

Fax: +886.2.2695.6933 Ext. 5313

Download English Version:

https://daneshyari.com/en/article/10748408

Download Persian Version:

https://daneshyari.com/article/10748408

<u>Daneshyari.com</u>